6 enrolling by invitation. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Enrolling by invitation 6 |
| Phase 1 | 2 | Enrolling by invitation 2 |
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Phase 2 | Enrolling by invitation | Johns Hopkins University | 40 | 2026-10-26 | 2026-11-03 |
| Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis Low molecular weight fucoidan and standard care, Placebo and standard of care - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Enrolling by invitation | Allama Iqbal Medical College | 90 | 2026-08-01 | 2026-08-26 |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD SPY001, SPY002, SPY003 - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Enrolling by invitation | Spyre Therapeutics, Inc. | 645 | 2026-06-08 | 2026-11-03 |
| Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy - Colorectal Cancer, Gastric Cancer | Phase 2 | Enrolling by invitation | Blokhin's Russian Cancer Research Center | 128 | 2025-06-03 | 2026-04-24 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI, Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI - Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation | Phase 1 / Phase 2 | Enrolling by invitation | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 102 | 2025-05-23 | 2026-09-25 |
| Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis Fecal microbiota transplantation (FMT) - Ulcerative Colitis, Fecal Microbiota Transplantation | Phase 2 / Phase 3 | Enrolling by invitation | Seoul National University Hospital | 30 | 2023-07-19 | 2025-09-12 |
Colitis, Ulcerative (3) · Colitis (2) · Colorectal Neoplasms (2) · Dysbiosis (1) · Inflammatory Bowel Diseases (1) · Irritable Bowel Syndrome (1) · Stomach Neoplasms (1) · Ulcer (1)
Digestive System Diseases (6) · Gastrointestinal Diseases (6) · Intestinal Diseases (6) · Gastroenteritis (3) · Digestive System Neoplasms (2) · Gastrointestinal Neoplasms (2) · Inflammatory Bowel Diseases (2) · Intestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Rectal Diseases (2) · Colitis (1)
Drug Therapy (1) · Fecal Microbiota Transplantation (1) · Folfox protocol (1) · Nivolumab (1) · Standard of Care (1)
Allama Iqbal Medical College (1) · Blokhin's Russian Cancer Research Center (1) · Johns Hopkins University (1) · Seoul National University Hospital (1) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1) · Spyre Therapeutics, Inc. (1)
South Korea (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · Georgia (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1)
Gerry Mullin, MD (1) · Rozina Shahadat Khan, MBBS, M.PHIL,MSPH, CHPE,PHDHND (1)
2025 (1)